2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
To assess the effects and the cost effectiveness of self monitoring of glucose in DM2 patients who are not using insulin on diabetes related distress, glycaemic control and changes in behavioural determinants.